1. 1165PImmune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas. (18th September 2017) Authors: Boileve, A.; Carlo, M.; Barthelemy, P.; Oudard, S.; Borchiellini, D.; Voss, M.; George, S.; Chevreau, C.; Landman-Parker, J.; Tabone, M-D.; Chism, D.; Amin, A.; Bilen, M.A.; Bosse, D.; Choueiri, T.K.; Tannir, N.; Malouf, G. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 64P Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with solid tumors and cardiac metastases. (December 2022) Authors: Nassar, A.H.; Zarif, T.; Abou Alaiwi, S.; Denu, R.; Macaron, W.; El-Am, E.; Malvar, C.; Ocejo Gallegos, J.A.; Cortellini, A.; Korolewicz, J.A.; Sackstein, P.; Aboubakar, F.; Foderaro, S.; Baena Espinar, J.; Woodford, R.; Grynberg, S.; Asnani, A.; Hayek, S.; Choueiri, T.K.; Naqash, A-R. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 76P Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials. (December 2022) Authors: Luke, J.J.; Long, G.V.; Robert, C.; Carlino, M.S.; Choueiri, T.K.; Haas, N.B.; O'Brien, M.E.R.; Paz-Ares, L.; Peters, S.; Powles, T.B.; Leiby, M.A.; Lin, J.; Zhao, Y.; Krepler, C.; Perini, R.F.; Pietanza, M.C.; Samkari, A.; Gruber, T.; Ibrahim, N.; Eggermont, A.M.M. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 854PDPazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm). (18th September 2017) Authors: Bossé, D.; McKay, R.R.; Gray, K.P.; Michaelson, M.D.; Sleeper, C.; Walsh, M.; Krajewski, K.M.; Jacene, H.; Bellmunt, J.; Pomerantz, M.M.; Harshman, L.C.; Choueiri, T.K. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study. (February 2017) Authors: Grande, E.; Choueiri, T.K.; Motzer, R.J.; Escudier, B.; Pal, S.; Kollmannsberger, C.; Pikiel, J.; Gurney, H.; Rha, S.Y.; Park, S.H.; Geertsen, P.F.; Gross Goupil, M.; Suarez, C.; Arroyo, A.; Dean, M.; George, D.; Powles, T. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study. (February 2017) Authors: Bracarda, S.; Choueiri, T.K.; Powles, T.; Motzer, R.J.; Olencki, T.; Frontera, O.A.; Oudard, S.; Rolland, F.; Tomczak, P.; Castellano, D.; Appleman, L.; Drabkin, H.; Vaena, D.; Milwee, S.; Youkstetter, J.; Escudier, B. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. Issue 11 (November 2015) Authors: Abdollah, F.; Sammon, J.D.; Reznor, G.; Sood, A.; Schmid, M.; Klett, D.E.; Sun, M.; Aizer, A.A.; Choueiri, T.K.; Hu, J.C.; Kim, S.P.; Kibel, A.S.; Nguyen, P.L.; Menon, M.; Trinh, Q.-D. Journal: European journal of surgical oncology Issue: Volume 41:Issue 11(2015:Nov.) Page Start: 1529 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). (February 2017) Authors: Schmidinger, M.; Motzer, R.J.; Powles, T.; Escudier, B.; Tannir, N.M.; Mainwaring, P.N.; Rini, B.I.; Hammers, H.J.; Donscov, F.; Roth, B.; Peltola, K.; Lee, J.L.; Heng, D.Y.C.; Aftab, D.T.; Hessel, C.; Scheffold, C.; Schwab, G.; Pal, S.; Hutson, T.E.; Choueiri, T.K. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗